宫颈癌新辅助化疗前后BAG-1、MCM2的表达及其与化疗疗效的相关性  

Expression of BAG-1 and MCM2 in Cervical Cancer before and after Neoadjuvant Chemotherapy and Its Correlation with Chemotherapy Efficacy

作　　者：宋丽娟[1] 向琳[3] 金荣[1] 康雅琼[1] 李晓琴[1] 魏春燕 戴银桥 张骞文[2] 狄晓鸿[2] SONG Li-juan;XIANG Lin;JIN Rong;KANG Ya-qiong;LI Xiao-qin;WEI Chun-yan;DAI Yinqiao;ZHANG Qian-wen;DI Xiao-hong(Department of Pathology,Gansu Provincial Cancer Hospital,Lanzhou 730050,China;Department of Gynecologic Oncology,Gansu Provincial Cancer Hospital,Lanzhou 730050,China;Department of Pathology,Lanzhou University Second Hospital,Lanzhou 730030,China)

机构地区：[1]甘肃省肿瘤医院病理科,兰州730050 [2]甘肃省肿瘤医院妇瘤科,兰州730050 [3]兰州大学第二医院病理科

出　　处：《国际妇产科学杂志》2020年第2期147-151,I0002,共6页Journal of International Obstetrics and Gynecology

基　　金：甘肃省卫生行业科研计划项目(GSWSKY-2015-33)。

摘　　要：目的:探讨B细胞淋巴瘤基因2结合致癌基因1(BAG-1)及微小染色体维持蛋白2(MCM2)作为宫颈癌新辅助化疗(NACT)有效性预测指标的可行性。方法:收集2015年1月2018年6月甘肃省肿瘤医院收治的90例术前以铂类为基础NACT方案化疗并手术治疗的宫颈癌患者临床资料,并选择60例同期因子宫肌瘤手术切除的正常宫颈组织作为对照。运用免疫组织化学方法检测正常宫颈组织以及同一宫颈癌患者NACT前宫颈活检组织及NACT后手术切除标本中BAG-1及MCM2蛋白的表达,比较正常宫颈与宫颈癌组织及NACT前、后宫颈癌组织中表达差异及其与NACT临床疗效的关系。结果:NACT前宫颈癌组织中BAG-1及MCM2高表达率分别为67.8%(61/90)和81.1%(73/90),高于正常宫颈组织的11.7%(7/60)和6.7%(4/60),差异有统计学意义(χ^2分别为45.736和76.909,均P=0.000)。NACT后宫颈癌组织中BAG-1及MCM2高表达率分别为70.0%(63/90)和78.9%(71/90),NACT前、后比较差异无统计学意义(χ^2分别为0.104和0.139,均P>0.05)。NACT后,90例宫颈癌患者中有效59例(65.6%),无效31例(34.4%),NACT疗效与年龄、病理类型、分化程度、肿瘤最大径线及国际妇产科联盟(FIGO)分期均无关(均P>0.05)。化疗有效组的BAG-1高表达率低于化疗无效组,差异有统计学意义(54.2%vs.93.5%,χ^2=12.636,P=0.000),而化疗有效组和化疗无效组的MCM2高表达率比较,差异无统计学意义(79.7%vs.83.9%,χ^2=0.235,P=0.628)。结论:BAG-1表达水平有可能成为预测宫颈癌以铂类为基础NACT方案疗效的参考指标。Objective:To explore the feasibility of BAG-1 and MCM2 as effective predictors for neoadjuvant chemotherapy(NACT)of cervical cancer.Methods:Clinical data of 90 patients of cervical cancer treated with preoperative platinum-based NACT and surgery were collected in Gansu Provincial Cancer Hospital from January 2015 to June 2018.Immunohistochemical methods were used to detect the expression of BAG-1 and MCM2 proteins in normal cervical tissues and cervical biopsy tissues of the same cervical cancer patients before NACT and after NACT.The expression differences between normal cervical tissues and cervical cancer tissues,cervical cancer tissues before and after NACT was compared,and the correlation of the 2 proteins with the clinical efficacy of NACT was analyzed.Results:The high expression rates of BAG-1 and MCM2 in pre-NACT cervical cancer tissues were 67.8%(61/90)and 81.1%(73/90),respectively,which was higher than 11.7%(7/60)and 6.7%(4/60)of normal cervical tissues.There was a significant difference between the two groups(χ^2=45.736 and 76.909,both P=0.000).The high expression rates of BAG-1 and MCM2 in cervical cancer tissues after NACT were 70.0%(63/90)and 78.9%(71/90),respectively.There was no significant difference between before and after NACT(χ^2=0.104 and 0.139,both P>0.05).After NACT,59 of 90 cases of cervical cancer were effective(65.6%),while 31 of 90 cases were invalid(34.4%).There was no correlation of the efficacy of NACT with age,pathological type,differentiation degree,tumor maximum diameter and FIGO stage(both P>0.05).The high expression rate of BAG-1 in the chemotherapy-effective group was lower than that ineffective group,and there was a significant difference between the two groups(54.2%vs.93.5%,χ^2=12.636,P=0.000).However,there was no significant difference of MCM2 high expression rate between the effective group and the ineffective group)79.7%vs.83.9%,χ^2=0.235,P=0.628).Conclusions:Detection of BAG-1 expression may be a reference indicator for predicting the chemotherapy efficacy of platinu

关 键 词：宫颈肿瘤 BAG-1 MCM2 免疫组织化学 新辅助化疗 治疗结果 

分 类 号：R737.33[医药卫生—肿瘤]